Cited by 362Prostate Cancer Treatment and ResearchRadiopharmaceutical Chemistry and ApplicationsProstate Cancer Diagnosis and Treatment

The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.

177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial

Open access

Morris, Michael J, Castellano, Daniel, Herrmann, Ken, de Bono, Johann S, Shore, Neal D, Chi, Kim N, Crosby, Michael, Piulats, Josep M, Fléchon, Aude, Wei, Xiao X, Mahammedi, Hakim, Roubaud, Guilhem, Študentová, Hana, Nagarajah, James, Mellado, Begoña, Montesa-Pino, Álvaro, Kpamegan, Euloge, Ghebremariam, Samson, Kreisl, Teri N, Wilke, Celine, Lehnhoff, Katja, Sartor, Oliver, Fizazi, Karim·2024·The Lancet

DOI 10.1016/s0140-6736(24)01653-2PMC PMC12121614

Open this paper in CoChat — free account

Abstract

Background [177 Lu]Lu-PSMA-617 (177 Lu-PSMA-617) prolongs radiographic progression-free survival and overall survival in patients with metastatic castration-resistant prostate cancer previously treated with androgen receptor pathway inhibitor (ARPI) and taxane therapy. We aimed to investigate the efficacy of 177 Lu-PSMA-617 in patients with taxane-naive metastatic castration-resistant prostate cancer.Methods In this phase 3, randomised, controlled trial conducted at 74 sites across Europe and North America, taxane-naive patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer who had progressed once on a previous ARPI were randomly allocated (1:1) to open-label, intravenous 177 Lu-PSMA-617 at a dosage of 7·4 GBq (200 mCi) ± 10% once every 6 weeks for six cycles, or a change of ARPI (to abiraterone or enzalutamide, administered orally on a continuous basis per product labelling). Crossover from ARPI change to 177 Lu-PSMA-617 was allowed after centrally confirmed radiographic progression. The primary endpoint was radiographic progression-free survival, defined as the time from randomisation until radiographic progression or death, assessed in the intention-to-treat population. Safety was a secondary endpoint. This study is registered with ClinicalTrials.gov (NCT04689828) and is ongoing. In this primary report of the study, we present primary (first data cutoff) and updated (third data cutoff) analyses of radiographic progression-free survival; all other data are based on the third data cutoff.Findings Overall, of the 585 patients screened, 468 met all eligibility criteria and were randomly allocated between June 15, 2021 and Oct 7, 2022 to receive 177 Lu-PSMA-617 (234 [50%] patients) or ARPI change (234 [50%]). Baseline characteristics were mostly similar between groups; median number of 177 Lu-PSMA-617 cycles was 6·0 (IQR 4·0-6·0). Of patients assigned to ARPI change, 134 (57%) crossed over to receive 177 Lu-PSMA-617. In the primary analysis (median time from randomisation to first data cutoff 7·26 months [IQR 3·38-10·55]), the median radiographic progression-free survival was 9·30 months (95% CI 6·77-not estimable) in the 177 Lu-PSMA-617 group versus 5·55 months (4·04-5·95) in the ARPI change group (hazard ratio [HR] 0·41 [95% CI 0·29-0·56]; p<0·0001). In the updated analysis at time of the third data cutoff (median time from randomisation to third data cutoff 24·11 months [IQR 20·24-27·40]), median radiographic progression-free survival was 11·60 months (95% CI 9·30-14·19) in the 177 Lu-PSMA-617 group versus 5·59 months (4·21-5·95) in the ARPI change group (HR 0·49 [95% CI 0·39-0·61]). The incidence of grade 3-5 adverse events was lower in the 177 Lu-PSMA-617 group (at least one event in 81 [36%] of 227 patients; four [2%] grade 5 [none treatment related]) than the ARPI change group (112 [48%] of 232; five [2%] grade 5 [one treatment related]).Interpretation 177 Lu-PSMA-617 prolonged radiographic progression-free survival relative to ARPI change, with a favourable safety profile. For patients with PSMA-positive metastatic castration-resistant prostate cancer who are being considered for a change of ARPI after progression on a previous ARPI, 177 Lu-PSMA-617 may be an effective treatment alternative.Funding Novartis.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(24)01653-2

Cites

47 of 47 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer
Tannock, I. F., de Wit, R., Berry, W. R., Horti, J., Pluzanska, A., Chi, K. N., Oudard, S., Théodore, C., James, N. D., Turesson, I., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040720 · Cited by 5,735
Self-citation
Integrative Clinical Genomics of Advanced Prostate Cancer
Robinson, D., Van Allen, E. M., Wu, Y.-M., Schultz, N., Lonigro, R. J., Mosquera, J.-M., Montgomery, B., Taplin, M.-E., Pritchard, C. C., Attard, G., et al. (2015) · Cell · doi:10.1016/j.cell.2015.05.001 · Cited by 3,645
Self-citation
Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer
Sartor, O., de Bono, J., Chi, K. N., Fizazi, K., Herrmann, K., Rahbar, K., Tagawa, S. T., Nordquist, L. T., Vaishampayan, N., El-Haddad, G., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107322 · Cited by 2,864
Self-citation
Olaparib for Metastatic Castration-Resistant Prostate Cancer
de Bono, J., Mateo, J., Fizazi, K., Saad, F., Shore, N., Sandhu, S., Chi, K. N., Sartor, O., Agarwal, N., Olmos, D., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1911440 · Cited by 2,323
Self-citation
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3
Scher, H. I., Morris, M. J., Stadler, W. M., Higano, C. S., Basch, E., Fizazi, K. S., Antonarakis, E. S., Beer, T. M., Carducci, M. A., Chi, K. N., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.2702 · Cited by 1,707
Self-citation
Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer
Pritchard, C. C., Mateo, J., Walsh, M. F., De Sarkar, N., Abida, W., Beltran, H., Garofalo, A., Gulati, R., Carreira, S., Eeles, R., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603144 · Cited by 1,680
Untitled work
(1997) · PubMed · Cited by 1,541
[177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study
Hofman, M. S., Violet, J. A., Hicks, R. J., Ferdinandus, J., Thang, S. P., Akhurst, T. J., Iravani, A., Kong, G., Kumar, A. S. R., Murphy, D. G., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30198-0 · Cited by 1,184
[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial
Hofman, M. S., Emmett, L., Sandhu, S., Iravani, A., Joshua, A. M., Goh, J. C., Pattison, D. A., Tan, T. H., Kirkwood, I. D., Ng, S., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00237-3 · Cited by 1,170
Defining the clinically important difference in pain outcome measures
Farrar, J. T., Portenoy, R. K., Berlin, J. A., Kinman, J. L., & Strom, B. L. (2000) · Pain · doi:10.1016/s0304-3959(00)00339-0 · Cited by 1,071

Show all 47 references

Research works printed but not linked: 1

Raychaudhuri, 2024, Genomic correlates of prostate-specific membrane antigen expression and response to 177Lu-PSMA-617: a retrospective multicenter cohort study, JCO Precis Oncol, 8

Sorted by citations

Items 201–300 of 362

Radionuklidtherapie 2025: Optionen der Nuklearmedizin in der Behandlung des metastasierten kastrationsresistenten Prostatakarzinoms
Willner, L., Tauber, R., & Eiber, M. J. (2025) · Die Urologie · doi:10.1007/s00120-025-02526-4
The role of radium-223 in the evolving treatment landscape of metastatic castration-resistant prostate cancer: A narrative review
Pinto, Á., Domínguez, M., Iturriaga, A. G., Rodríguez‐Vida, A., Casas, J. A. V., & Castro, E. (2025) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2025.104678
Theranostik in der Nuklearmedizin
Langbein, T., Pfestroff, A., & Eilsberger, F. (2025) · Die Onkologie · doi:10.1007/s00761-025-01699-z
Expert Opinion on Current Treatment Alternatives for Patients With Prostate Cancer Progressing From the Metastatic Hormone-Sensitive Stage to the Castration-Resistant Stage After Receiving Early Treatment Intensification
Vázquez, S., Gallardo, E., Calvo, O. F., Juan-Fita, M. J., Pino, Á. M., Lázaro-Quintela, M., Anido, U., & del Alba, A. G. (2025) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2025.102338
Systemic treatment options for metastatic castration resistant prostate cancer: A living systematic reviewPreprint
Naqvi, S. A. A., Anjum, M. U., Bibi, A., Khan, M. A., Khakwani, K. Z. R., He, H., Imran, M., Kazmi, S. Z., Raina, A., Cobran, E. K., et al. (2025) · medRxiv · doi:10.1101/2025.04.15.25325837 · Cited by 1
Self-citation
Revolucionando el tratamiento del cáncer de próstata: la terapia dirigida al antígeno prostático específico en el enfoque moderno terapéutico
Ricaurte‐Fajardo, A., Corzo, V. M., Ruder, S. F., Cardoza-Ochoa, D. R., Granados, C., Yadav, D., Lopez, D., Fatima, M., Dutruel, S. P., O’Dwyer, E., et al. (2025) · Revista Española de Medicina Nuclear e Imagen Molecular · doi:10.1016/j.remn.2025.500162
Baseline Hematological Parameters and Outcomes in Patients With Prostate Cancer Treated With Lu-177 PSMA Radioligand Therapy (RLT): A Multicenter Real-World Analysis
Bergstrom, C. P., Chalker, C., Allen, J. D., Hong, S., Yilmaz, B., Sokolova, A. O., & Khaki, A. R. (2025) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2026.102569
Navigating the prostate cancer frontiers: charting new horizons in molecular imaging and targeted radionuclide therapy
Al‐Ibraheem, A. (2025) · The Quarterly Journal of Nuclear Medicine and Molecular Imaging · doi:10.23736/s1824-4785.25.03644-1
4. Moves towards Establishing a Domestic System for Targeted Radionuclide Therapy
Higashi, T. (2025) · Japanese Journal of Radiological Technology · doi:10.6009/jjrt.25-0703
Update Nuklearmedizin 2025: Theranostik
Bundschuh, R. A., Enke, J. S., Brinkmann, E., Voltin, C., & Brenner, W. (2025) · Die Onkologie · doi:10.1007/s00761-025-01794-1
Nuklearmedizinische Optionen bei fortgeschrittenem Prostatakarzinom in der Praxis
Kunte, S. C., Kazmierczak, P. M., Holzgreve, A., Stief, C. G., Casuscelli, J., Unterrainer, M., & Unterrainer, L. M. (2025) · Die Urologie · doi:10.1007/s00120-025-02659-6
PSMA-Radioligandentherapie – State of the Art
Berliner, C., Grünwald, V., Krafft, U., Himmen, S., & Fendler, W. P. (2025) · Die Urologie · doi:10.1007/s00120-025-02661-y · Cited by 1
Advances in Radiotherapy of Genitourinary Cancers
Paul, D., Bhui, U., Das, J., Debnath, B., Mondal, M., Ashique, S., & Sheikhmiri, S. (2025) · Springer eBooks · doi:10.1007/978-3-031-95724-6_11
Shaping the future of 177Lu-PSMA-617 radiopharmaceutical therapy in prostate cancer: is earlier better, or is patient selection key?
Azad, A., & Hofman, M. S. (2025) · Annals of Oncology · doi:10.1016/j.annonc.2025.09.002
Lettre à l’éditeur au sujet de l’article « Innovation thérapeutique et enjeux capacitaires en médecine nucléaire : la situation de la RIV en Occitanie » par Guignard et al. (1)
Courbon, F., Kotzki, P. O., Boudousq, V., Fersing, C., Salaün, P., & Deshayes, E. (2025) · Médecine Nucléaire · doi:10.1016/j.mednuc.2025.06.008
Nuklearmedizinische Optionen bei fortgeschrittenem Prostatakarzinom in der Praxis
Siegmund, S. C., Kazmierczak, P. M., Holzgreve, A., Stief, C. G., Casuscelli, J., Unterrainer, M., & Unterrainer, L. M. (2025) · best practice onkologie · doi:10.1007/s11654-025-00690-9
6. Global Trends in Beta-Emitter Radioligand Therapy
Hotta, M. (2025) · Japanese Journal of Radiological Technology · doi:10.6009/jjrt.25-0902
Deep and Durable Prostate-Specific Antigen Response Following Comprehensive Involved Site Radiotherapy for Prostate Cancer Oligometastases
Schmalzle, M., Kaur, M., Radigan, R., Atalla, C. S., Sygaco, E., Pandey, M., & Kao, J. (2025) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2025.06.3049
Advances in Prostate Cancer Treatment: Exploring Molecular Targets and New Strategies in Castration-Resistant Disease
Gopi, P., Ishfaq, M., Das, S. K., Shkoukani, Z. W., Khattak, A. Q., Gana, H. B., Mistry, R., Jones, R. E., Chamsin, A., & Hughes, K. E. (2025) · Cureus · doi:10.7759/cureus.94427 · Cited by 5
Therapeutic targeting of prostate-specific membrane antigen could limit its potential as benchmark imaging
Abel, M. L., Sharp, A., Posadas, E. M., Karzai, F. H., Lin, F. I., Choyke, P. L., & Madan, R. A. (2025) · Nature Reviews Urology · doi:10.1038/s41585-025-01100-z
Nuklearmedizinische Optionen bei fortgeschrittenem Prostatakarzinom in der Praxis
Siegmund, S. C., Kazmierczak, P. M., Holzgreve, A., Stief, C. G., Casuscelli, J., Unterrainer, M., & Unterrainer, L. M. (2025) · Die Radiologie · doi:10.1007/s00117-025-01527-w
Radiopharmaceutiques à visée thérapeutique : indications, précautions d’emploi et principaux résultats
Bailly, C., Lugat, A., & Garin, É. (2025) · EMC - Radiologie et imagerie médicale - Principes et techniques - Radioprotection · doi:10.1016/s1879-8497(25)49589-2
Concordance between single-time-point and multiple-time-point dosimetry in 177Lu-PSMA-I&T therapy for metastatic castration-resistant prostate cancer
Barbosa, N., Granados, C., Pulido, E., & Zuluaga, C. (2025) · Nuclear Medicine Communications · doi:10.1097/mnm.0000000000002076
Lutetium Lu 177 vipivotide tetraxetan: A literature review
Morrison, G., & Holle, L. M. (2025) · Journal of Oncology Pharmacy Practice · doi:10.1177/10781552251392083 · Cited by 1
Nuclear Medicine Imaging Techniques for Prostate Cancer
Daisaki, H., Kamiya, T., & Fukai, S. (2025) · Japanese Journal of Radiological Technology · doi:10.6009/jjrt.25-1105
[ 68 Ga]Ga-DOTA-CEND1: A Novel PET Cyclic Peptide Tracer for Noninvasive Imaging of Neuropilin-1 Expression in Pan-Tumors
Qiu, F.-H., Tang, S., Liu, X., Lei, J., Bian, L., Zhang, F., Pan, X., Xu, X., He, S., Zhang, J., et al. (2025) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5c01160 · Cited by 1
Targeted radionuclide therapies for prostate cancer: clinical insights and innovation
Rasul, S., & Einspieler, H. (2025) · memo - Magazine of European Medical Oncology · doi:10.1007/s12254-025-01089-6
Shining the PSMA spotlight on peritoneal metastases in prostate cancer
Kuten, J., Chahwan, S., White, C., Mauguen, A., Schöder, H. M., & Krebs, S. S. (2025) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-025-07703-3
Conventional versus Monte Carlo SPECT reconstruction of Lu‐177: Toward reduced bias and variance in quantitative imaging
Polson, L., Esquinas, P. L., Kurkowska, S., Li, C., Uribe, C., & Rahmim, A. (2025) · Medical Physics · doi:10.1002/mp.70222
Reply to Tonghu Liu, Congcong Zhu, and Zechen Yan’s Letter to the Editor re: Heidi Fettke, Louise Kostos, Maria Docanto, et al. Baseline and Early On-treatment Circulating Tumour DNA Fraction Are a Key Prognostic Biomarker in Metastatic Castration-resistant Prostate Cancer Treated with [177Lu]Lu-PSMA-617. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2025.08.015
Kostos, L. K., Fettke, H., Tu, N.-D., Hofman, M. S., & Azad, A. (2025) · European Urology Focus · doi:10.1016/j.euf.2025.12.012
Clinical Significance of Radioligand Therapy with 177Lu-DOTATATE and the Role of Pharmacists
Kano, D. (2026) · Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences) · doi:10.5649/jjphcs.52.1
PET-imaging derived prognostic factors for prostate cancer patients with visceral metastases receiving [177Lu]Lu-PSMA radiopharmaceutical therapy (RPT)
Späth, M. S., Dittmann, H., Spallek, R., Calderón, E., Mück, J., Brendlin, A., Rausch, S., la Fougère, C. J., & Trautwein, N. F. (2026) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-025-07712-2
p21 CIP1/WAF1 -mediated partial senescence supports steroidogenesis and therapy resistance in primary prostate cancer culturesPreprint
Toscano, E., Maggio, V., Alvarez-Meythaler, J. G., Garcia, J., Celma, A., Planas, J., Semidey, M. E., Marín‐Aguilera, M., Somoza, R., Mellado, B., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.01.15.699666
Self-citation
Radioligandentherapie des metastasierten, kastrationsresistenten Prostatakarzinoms
Dahlke, P. M., Ruhwedel, T., & Rogasch, J. M. M. (2025) · Springer Reference Medizin · doi:10.1007/978-3-662-46764-0_398-1
Clinical Dosimetry Models and Pathway to Integration in Routine Nuclear Medicine Practice
Akerele, M. I., Singh, B., Mikell, J., Kaur, K., Prasad, V., & Laforest, R. A. (2026) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000006180
Clinical research analysis of [225Ac]Ac-PSMA-617 therapy for [177Lu]Lu-PSMA-refractory metastatic castration-resistant prostate cancer
Rao, Z., Ma, J., Yangqing, J., Yang, W., Zhang, F., Hu, M., Zhang, C., & Chen, Y. (2026) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-026-07778-6
Radioligand therapy with 177Lu-PSMA in castration-resistant prostate cancer: a literature review and case series
Волкова, М. И., Krylov, A. S., Nosov, D., & Alekseev, B. Y. (2026) · Journal of Modern Oncology · doi:10.26442/18151434.2025.4.203504
[177Lu]Lu-PSMA radioligand therapy in systemic therapy-naïve metastatic hormone-sensitive prostate cancer patients: a retrospective study
Langrate, I. K., Ofner, H., Kretschmer‐Chott, E., Einspieler, H., Kulterer, O. C., Schmitl, S., Nics, L., Shariat, S. F., Hacker, M., Rasul, S., et al. (2026) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-026-07802-9
Biología molecular del cáncer de próstata
Puentes, L. L. R., Chavarriaga-Soto, J., Zuluaga, J. A., Báez, C. A. V., & Bourlon, M. T. (2026) · Revista Colombiana de Hematología y Oncología · doi:10.51643/22562915.854
Neue Arzneimittel 2024
Seifert, R., & Rauch, B. H. (2026) · Springer eBooks · doi:10.1007/978-3-662-72738-6_2
Emerging Theranostic Targets in Squamous Cell Carcinoma of the Head and Neck
Kunte, S. C., Serfling, S. E., Higuchi, T., Buck, A. K., Canis, M., Reichel, C. A., & Werner, R. A. (2026) · Nuklearmedizin - NuclearMedicine · doi:10.1055/a-2800-7670
Positron Emission Tomography/Computed Tomography Imaging with [18F]PARPi for Precision Guidance of Poly ADP-ribose Polymerase Inhibitor Therapy in Homologous Recombination Repair Mutated and Nonmutated Metastatic Castration-resistant Prostate Cancer
Ofner, H., Einspieler, H., Ozenil, M., Spielvogel, C. P., Langrate, I. K., Bamminger, K., Hassler, M. R., Baltzer, P., Shariat, S. F., Hacker, M., et al. (2026) · European Urology Oncology · doi:10.1016/j.euo.2026.02.012
[177Lu]Lu-PSMA radioligand therapy in younger prostate cancer patients: A matched-pair analysis between patients ≤ 65 and ≥ 70 years old
Hornfeck, J., Dahlmann, P., Siegmund, S. C., Gildehaus, F. J., Delker, A., Schmidt-Hegemann, N.-S., Bundschuh, R. A., Zacherl, M. J., Klimek, K., Casuscelli, J., et al. (2026) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-026-07817-2
Monitoring of Disease in Patients Receiving 177LU-PSMA-617 Therapy in Routine Practice
Rashid, N. S., Zhong, C., Xie, W., Stoltenberg, H., Wolanski, A., Ritzer, J., Jacene, H. A., & Ravi, P. K. (2026) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2026.102532
Complete Response to Pembrolizumab in Prostate Cancer With Microsatellite Instability–High, Deficient Mismatch Repair, Tumor Mutational Burden–High, and Programmed Death–Ligand 1 Positivity
Wise, T., Heins, J., Schieber, T. J., & Parikh, R. A. (2026) · Annals of Internal Medicine Clinical Cases · doi:10.7326/aimcc.2025.1017
131I-LNTH-1095 Radioligand Therapy plus Enzalutamide versus Enzalutamide Alone in Men with PSMA-Avid Metastatic Castration-Resistant Prostate Cancer: A Phase II Study
Yu, E. Y., Narayan, V., Esposito, G., Szmulewitz, R. Z., Lu, Y., Lilly, M. B., Calais, J., Bratslavsky, G., Menda, Y., Vasanawala, M., et al. (2026) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-25-4948 · Cited by 1
Prostate-Specific Membrane Antigen Radioligand Therapy in Patients with Aggressive-Variant Prostate Cancer
Moradpour, M., Tuchayi, A. M., Yadav, S., Jiang, F., Burger, I. A., Pop, S. G., Surasi, D. S., Hussein, A., Arora, I., Aparicio, A. M., et al. (2026) · Journal of Nuclear Medicine · doi:10.2967/jnumed.125.271296
Treatments on the Horizon for Men with Advanced Prostate Cancer
Ehrlich, M. I., Gejman, R. S., Bernstein, E., & Stein, M. N. (2026) · Urologic Clinics of North America · doi:10.1016/j.ucl.2026.02.014
Outcome and safety of single-dose docetaxel–augmented targeted radionuclide therapy using [¹⁷⁷Lu]Lu-PSMA-617 radioligand therapy in treatment-refractory mCRPC: preliminary evidence from a pilot experience
Ebert, N., Rosar, F., Burgard, C., Bartholomä, M. D., Maus, S., Hein, C., Blickle, A., Ezziddin, S., & Khreish, F. (2026) · EJNMMI Research · doi:10.1186/s13550-026-01408-w
Steady progress in the treatment of advanced prostate cancer: a year in review
Gourdin, T. S. (2026) · Current Opinion in Oncology · doi:10.1097/cco.0000000000001237 · Cited by 1
Prostate-Specific Membrane Antigen Theranostics in Prostate Cancer – Current State and Evolving Standards
Satapathy, S., Chandekar, K. R., & Damle, N. (2026) · PET Clinics · doi:10.1016/j.cpet.2026.02.002
Aktualisierung S3-Leitlinie zum metastasierten Prostatakarzinom – Leitlinienempfehlungen und Expertenkonsens
Grimm, M., Gratzke, C., Hadaschik, B. A., Eiber, M., Herrmann, K., Hellmis, E., Klier, J., Kristiansen, G., Wiedemann, A., Merseburger, A. S., et al. (2026) · Die Urologie · doi:10.1007/s00120-026-02817-4
Self-citation
Assessment of nephrotoxicity following lutetium-177 PSMA I&T radioligand therapy: a comparative study with docetaxel chemotherapy
Kirchhoff, F. P., Steinhelfer, L., Pfob, C. H., Lapa, C., Hartrampf, P. E., Buck, A. K., Tauber, R., Schäfer, H., Schmaderer, C., Fütterer, C., et al. (2026) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-026-07890-7
177 Lu-PSMA-617 radioligand therapy as an immune modulator in prostate cancer
Sciortino, C., Nuzzo, A., Stellato, M., Claps, M., Rametta, A., Guadalupi, V., Gusmaroli, E., Rota, S., Mascaro, F., Giannatempo, P., et al. (2026) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2026.2657914
Optimizing Care for Patients With Metastatic Castration-Resistant Prostate Cancer
Cren, P., Buteau, J. P., Fatema, U., Patel, R., Saraiya, B., Emmett, L., & Fizazi, K. S. (2026) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk-26-516658
Self-citation
The emerging role of prostate-specific membrane antigen–targeted radioligand therapy in metastatic hormone-sensitive prostate cancer
Mulugeta, P. G., Dorff, T. B., Hafron, J. M., Huynh, M. A., Morgans, A. K., Ross, A. E., & McKay, R. R. (2026) · The Oncologist · doi:10.1093/oncolo/oyag173
Response assessment in [177Lu]PSMA: where do we stand?
Guglielmo, P., Aghaee, A., Sadeghpour, S., Eccles, A., & Evangelista, L. (2026) · The Quarterly Journal of Nuclear Medicine and Molecular Imaging · doi:10.23736/s1824-4785.26.03719-2
The predictive role of [177Lu]Lu-PSMA-617 SPECT/CT semiquantitative parameters from the 1st RLT cycle in advanced mCRPC: a preliminary bicentric lesion-based analysis
Laudicella, R., Celesti, G., Bauckneht, M., Micali, A., Midili, F., Bucca, A., Ferro, V. M., Piergentili, M., Ricciardello, G., Brogna, A., et al. (2026) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-026-07927-x
Quantitative SPECT/CT: Technique and Clinical Applications
Schepper, S. D., WYNGAERT, T. V. D., Ritt, P., & Kuwert, T. (2026) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-032-21415-7_1
Targeted Radiopharmaceutical Therapy: Advances, Investment Dynamics, and Future Directions—Part 1
Somma, C., Zimmermann, R., Gericke, G., & Herrmann, K. (2026) · Journal of Nuclear Medicine · doi:10.2967/jnumed.125.270855
Self-citation
A Call for High-Level Evidence Before Routine Implementation of Posttreatment SPECT
Mulugeta, P. G., O’Brien, S. R., Mankoff, D. A., Sartor, O., & Taunk, N. K. (2026) · Journal of Nuclear Medicine · doi:10.2967/jnumed.125.271508
Self-citation
Impact of PSMA-Based Radiopharmaceuticals on the Clinical Management of Prostate Cancer
Guida, C., Evangelista, L., Spadafora, M., Facchini, G., & Mansi, L. (2026) · Cancers · doi:10.3390/cancers18111799
PSMA theranostics in the evolving landscape of metastatic prostate cancer: challenges and opportunities
Wang, X., Holler, S. D., & Hogan, T. F. (2026) · ONCOLOGIE · doi:10.1515/oncologie-2025-0571
Publication trends and knowledge structure of prostate-specific membrane antigen radioligand therapy for prostate cancer: a bibliometric analysis, 2015–2025
Long, H., Qiao, X.-H., Li, X. J., Kong, X., & Liu, Q.-W. (2026) · Nuclear Medicine Communications · doi:10.1097/mnm.0000000000002193
Acute complications of nuclear medicine: an emergency medicine perspective
Sutaşır, M. N., Arslan, B., Mohamed, M. M., & Hökenek, N. M. (2026) · EJNMMI Research · doi:10.1186/s13550-026-01464-2
177Lutetium-PSMA-I&T therapy for metastatic castration-resistant prostate cancer (mCRPC): the first multicenter real-world study of 177Lu-PSMA-I&T in Brazil
Bruzzi, H. F., Lopes, G. C. K., Bekierman, H. B. V., de Almeida, S. A., Pedrosa, J. A., Mosci, C., Abboud, H. S., Magalhães, C., Palazzio, I., Fernandes, L., et al. (2026) · EJNMMI Reports · doi:10.1186/s41824-026-00305-8
Achieving consensus for the management of Lutetium-PSMA radioligand therapy in metastatic castration-resistant prostate cancer in Sicily
Laudicella, R., Galanti, D., Alongi, P., Aricò, D., Castorina, L., Cicero, G., D’Agostino, G., D’Angelo, A., Federico, M., Ippolito, M., et al. (2026) · Clinical and Translational Imaging · doi:10.1007/s40336-026-00781-9
Liver Background Uptake of Prostate-specific Membrane Antigen–targeted PET Radiotracers: A Systematic Review and Meta-Analysis
Ulaner, G. A., Parihar, A. S., Calais, J., Sutcliffe, S., & Schoones, J. W. (2026) · Radiology Imaging Cancer · doi:10.1148/rycan.250732
Reply to: Prostate-Specific Membrane Antigen Positron Emission Tomography and Radiometabolic Therapies in Metastatic Castration-Resistant Prostate Cancer
Riaz, I. B., Rumble, R. B., Hope, T. A., Procopio, G., & Vapiwala, N. (2026) · Journal of Clinical Oncology · doi:10.1200/jco-26-01001
How will PLUDO, PSMAfore, SPLASH, and ECLIPSE Impact Prostate Cancer Management?
Beauregard, J., Ong, M., & Pouliot, F. (2026) · European Urology Focus · doi:10.1016/j.euf.2026.06.013
Prognostic Value of Restaging [ 18 F]FDG PET/CT in Patients with Metastatic Castration-Resistant Prostate Cancer Undergoing [ 177 Lu]Lu-PSMA-617 Therapy
Kashyap, R. K., Buteau, J. P., Papa, N. P., Ayati, N., Eifer, M., Betech-Antar, V., Akhurst, T. J., Alipour, R., Kong, G., Saghebi, J., et al. (2026) · Journal of Nuclear Medicine · doi:10.2967/jnumed.126.272531
Radiation-Induced Senescence in Radiopharmaceutical Therapy: Mechanisms and Therapeutic Implications
Lindsey, M. J., & Hernandez, R. (2026) · Journal of Nuclear Medicine · doi:10.2967/jnumed.126.272389
Radioligand Therapy for Prostate Cancer – A Clinical Consultation Guide
Hennes, D. M. Z. B., Al-Khanaty, A., Monna, M., Lawrentschuk, N., Perera, M., Eapen, R. S., Buteau, J. P., Hofman, M. S., & Murphy, D. G. (2026) · European Urology Focus · doi:10.1016/j.euf.2026.06.014
Prognostic value of circulating tumor DNA and copy-number alterations in patients receiving tandem [225Ac]Ac-/[177Lu]Lu-PSMA-617 therapy for metastatic castration-resistant prostate cancer: a prospective observational study
Amghar, M., Hielscher, T., Rausch, T., Ozgur, H., Bauder‐Wüst, U., Rathke, H. G., Bruchertseifer, F., Morgenstern, A., Roscher, M., Beneš, V., et al. (2026) · BMC Cancer · doi:10.1186/s12885-026-16791-9
PARP inhibition combined with a T-cell receptor β chain-directed antibody fusion molecule drives polyclonal antitumor immunity and tumor regression
Santiago-Sánchez, G. S., Rosato, F., Fabian, K. P., Padget, M. R., Lee, J.-M., Karzai, F. H., Schlom, J., Gulley, J. L., Hamilton, D. H., Lee, J. K., et al. (2026) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-014518
The PSMA paradox: How biology, androgen signaling, and therapy sequencing shape Lu-177 efficacy
Önder, A. H. (2026) · Current Radiopharmaceuticals · doi:10.1016/j.craph.2026.100069
Individualization of systemic treatment for advanced prostate cancer
Katolická, J. (2026) · Onkologie · doi:10.36290/xon.2026.024
From detection to destruction: a theranostic approach to prostate cancer
Ičová, V., Quinn, L., Henzlová, L., & Kamínek, M. (2026) · Onkologie · doi:10.36290/xon.2026.028
The Prognostic Value of 68Ga-PSMA and 18F-FDG PET/CT in Metastatic Castration-Resistant Prostate Cancer Treated with 177Lu-EB-PSMA
Chen, X., Peng, Y., Zheng, Q., Lai, Y., Cheng, H., Zhu, Z., Wang, G., & Zang, J. (2026) · Annals of Nuclear Medicine · doi:10.1007/s12149-026-02250-9
Overall Survival with [ 177 Lu]Lu-PSMA-617 Versus [ 177 Lu]Lu-PSMA I&T: A Propensity Score–Matched Real-World Analysis
Hasenauer, N., Probst, C., Schlötelburg, W., Jedamzik, T., Heinrich, M., Zindler, N., Buck, A. K., Seitz, A. K., & Hartrampf, P. E. (2026) · Journal of Nuclear Medicine · doi:10.2967/jnumed.126.272415
PSMA Theranostics in Prostate Cancer: From Standardized PET Imaging to Clinical Implementation of Radioligand Therapy
Iijima, S., Utsumi, T., Ikeda, R., Sugimoto, T., Ishitsuka, N., Kadono, Y., Noro, T., Suzuki, Y., Sugizaki, Y., Somoto, T., et al. (2026) · Applied Sciences · doi:10.3390/app16136590
Personalized therapy in metastatic hormone-sensitive prostate cancer: a 2026 update on navigating therapeutic complexity
Koett, M., Artamonova, N., & Heidegger, I. M. (2026) · Current Opinion in Urology · doi:10.1097/mou.0000000000001423
PSMA-Targeted Radioligand Therapy Beyond the Post-Taxane Setting: A Review of Evidence Across the Prostate Cancer Spectrum
Wang, K., Hassanbhai, D. H., Teo, R. Y. A., Ong, C. S. H., Lai, K. W., Koo, S. X., Yam, W. L., & Tung, J. Y. M. (2026) · Cancers · doi:10.3390/cancers18132161
Documento de consenso práctico sobre el uso de [177Lu]Lu-PSMA-617 en el cáncer de próstata metastásico resistente a la castración
Mena, N. Á., Gómez‐Grande, A., Seoane, Z. N., Prado-Wohlwend, S., Fernández, A. R., Fraile, M. R., Vercher-Conejero, J. L., & Casanovas, M. M. (2026) · Revista Española de Medicina Nuclear e Imagen Molecular · doi:10.1016/j.remn.2026.500336
Radioligand therapy for pediatric patients with solid tumors
Teles, L., Tolboom, N., Poot, A. J., Ramdhani, K., Plasschaert, S. L. A., Merks, J. H. M., van Noesel, M. M., & Braat, A. J. A. T. (2026) · British Journal of Radiology · doi:10.1093/bjr/tqag161
Treatment Patterns and Survival Outcomes in a Real-World Cohort of Lutetium 177 Vipivotide Tetraxetan (LuPSMA)-Experienced Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC)
Tran, B., Dorff, T. B., Richey, M., Hankinson, E. A., Olsen, P., Karwa, S., Sharpe, J., Braunlin, M., & Kim, C. (2026) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2026.102609
Prostate-specific membrane antigen based diagnostic and therapeutic integration for prostate cancer management
Dixit, T., Sawardekar, M., Verma, T., Sreeja, P., & Ravindran, S. (2026) · Discover Oncology · doi:10.1007/s12672-026-05554-4
Targeting the tumor microenvironment in genitourinary cancers: current progress and future directions in prostate cancer
Slovin, S. F. (2026) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2026.2701337
Targeted Radionuclide Therapy: Current Landscape and Combination Approaches to Improve Oncology Outcomes
Nonnekens, J., Byers, L. A., Chauhan, A., George, D. J., Hicks, R. J., & Weber, W. (2026) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-25-4720
Treatment and Outcomes of Patients With Metastatic Castration-resistant Prostate Cancer by Race, Initial Diagnosis, and Family History: Results From the TRUMPET Registry
Karsh, L. I., Hwang, C., Symanowski, J., Shevrin, D. H., Elsouda, D., Russell, D., Spalding, J. R., Kráľ, P., El-Chaar, N. N., & Shore, N. D. (2026) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2026.102615
Self-citation
Baseline PSMA PET/CT Biomarkers for Patient Selection in [177Lu]Lu-PSMA Radioligand Therapy: Clinical Promise, Methodological Heterogeneity and Future Standardization
Galnaitienė, G., Simkus, M., Balčiūnaitė, I., Lušaitė, K., Wen, F., Hoffmann, M., Saar, M., Mottaghy, F. M., Vajauskas, D., & Lütje, S. (2026) · Pharmaceuticals · doi:10.3390/ph19071084
PSMA-targeted radioligand therapy in advanced prostate cancer: a narrative review of ^177Lu-PSMA, emerging ^225Ac-PSMA strategies, and therapeutic sequencing
Gierulska, N., Jankowska, N., Kwiatkowska, A., Kuchno, P., Łysak, K., Szklener, K., Kośmider, K., & Skórzewska, M. (2026) · Oncology Reviews · doi:10.3389/or.2026.1834484
Actinium-225-rhPSMA-10.1 as a novel, alpha-particle-emitting therapy for prostate cancer: results of a preclinical evaluation
Foxton, C., Waldron, B. P., Wurzer, A. J., D’Alessandria, C., Morgenstern, A., Bruchertseifer, F., Nielsen, T. K., Grønlund, R. V., Hallund, M. W., & Stevens, D. J. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1868487
Comparator-dependent evidence for earlier PSMA-targeted radioligand therapy in prostate cancer: a systematic review and meta-analysis of randomized trialsPreprint
Wu, H., Zhang, W., Yan, X., Liu, X., Liu, A., Yang, L., Song, P., & Dong, Q. (2026) · Research Square · doi:10.21203/rs.3.rs-10243396/v1
Crossover does not confound, it informs: 177lutetium-PSMA-617 as an example
Schoen, M. W., Fojo, T., & Bono, J. S. D. (2026) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-026-01182-7
Lutetium-177–PSMA radioligand therapy in metastatic hormone-sensitive prostate cancer: A systematic review of efficacy, safety, and combination strategies
McGrath, J., Willis, R. G., Balaji, S., Ishiyama, Y., Sceats, H., Bandyk, M., & Balaji, K. C. (2026) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2026.06.028
Tumor microenvironment-mediated hematologic toxicity of 225Ac-PSMA-617 in metastatic castration-resistant prostate cancer: mechanisms, risk stratification, and clinical management
Wang, Z., 輝, 小., Wang, B., Tang, W., Liang, G., & Wu, T. (2026) · World Journal of Urology · doi:10.1007/s00345-026-06620-w
Dose-intensified PSMA Radioligand Therapy: The Rationale Behind the OPTIMAL-PSMA Trial
Sheehan‐Dare, G., Khan, S., & Emmett, L. (2026) · European Urology Focus · doi:10.1016/j.euf.2026.07.006
WSB1-Mediated PSMA Ubiquitination Promotes Enzalutamide-Induced Neuroendocrine-like Transition in Patient-Derived Prostate Cancer Spheroids
Jung, D., Kendi, A. T., Woodrum, D. A., Adamo, D. A., Thompson, S. M., In, M., Bilgin, G. B., Johnson, D. R., Horn, I. M., Kim, E.-J., et al. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27156899
Real-World Outcomes of [ 177 Lu]Lu-PSMA-617 in the French Early-Access Program for Patients with Metastatic Castration-Resistant Prostate Cancer
Bailly, C., Vija, L., Somme, F., Massard, V., Barthélémy, P., Giraudet, A., Godbert, Y., Fléchon, A., Girault, S., Abadie‐Lacourtoisie, S., et al. (2026) · Journal of Nuclear Medicine · doi:10.2967/jnumed.126.272721
Self-citation

Authors: Morris, M. J., Castellano, D., Herrmann, K., de Bono, J. S., Shore, N. D., Chi, K. N., Crosby, M., Piulats, J. M., Fléchon, A., Wei, X. X., Mahammedi, H., Roubaud, G., Študentová, H., Nagarajah, J., Mellado, B., Montesa-Pino, Á., Kpamegan, E., Ghebremariam, S., Kreisl, T. N., Wilke, C., Lehnhoff, K., Sartor, O., & Fizazi, K.
Affiliations: Memorial Sloan Kettering Cancer Center (US)
Research Institute Hospital 12 de Octubre (ES)
National Center for Tumor Diseases (DE)
Carolina Urologic Research Center (US)
BC Cancer Agency (CA)
Institut Català d'Oncologia (ES)
Centre Léon Bérard (FR)
Dana-Farber Cancer Institute (US)
Centre Jean Perrin (FR)
Institut Bergonié (FR)
University Hospital Olomouc (CZ)
Radboud University Medical Center (NL)
Hospital Clínic de Barcelona (ES)
Novartis (Switzerland) (CH)
Mayo Clinic (US)
Université Paris-Saclay (FR)
Corresponding author: Morris, Michael J
ORCID: Morris, Michael J
Castellano, Daniel
Shore, Neal D
Chi, Kim N
Piulats, Josep M
Fléchon, Aude
Wei, Xiao X
Mahammedi, Hakim
Študentová, Hana
Nagarajah, James
Mellado, Begoña
Kreisl, Teri N
Fizazi, Karim
Venue: The Lancet
Publisher: Elsevier BV
Published: 2024-09
Volume: 404
Issue: 10459
Pages: 1227-1239
ISSN: 0099-5355 (ISSN-L)
0140-6736
DOI: 10.1016/s0140-6736(24)01653-2
PMC: PMC12121614
OpenAlex: W4402552580
Cited by: 362
References: 47
Citations by year: 2026: 204 · 2025: 150 · 2024: 8
FWCI: 104.54
Type: journal article
Language: en
Update notices: erratum (2024-12-21)
Open access: green
pmc.ncbi.nlm.nih.gov
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
doi.org/10.15223/policy-017 (stm-asf)
doi.org/10.15223/policy-037 (stm-asf)
doi.org/10.15223/policy-012 (stm-asf)
doi.org/10.15223/policy-029 (stm-asf)
doi.org/10.15223/policy-004 (stm-asf)
Locations: The Lancet (publishedVersion)
PubMed (publishedVersion)
PubMed Central (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
Radboud Repository (Radboud University) (submittedVersion)
Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
Funders: Novartis Pharmaceuticals Corporation
Novartis
National Institutes of Health
National Cancer Institute (P30 CA008748)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Radiopharmaceutical Chemistry and Applications
Health Sciences › Medicine › Urology › Prostate Cancer Diagnosis and Treatment
Keywords: 177Lu-PSMA-617, androgen receptor pathway inhibitors, abiraterone, enzalutamide, radiographic progression-free survival, radiographic progression, overall survival, radioligand therapy
MeSH terms: Progression-Free Survival, Aged, Androstenes, Benzamides, Dipeptides, Heterocyclic Compounds, 1-Ring, Humans, Lutetium, Male, Middle Aged, Nitriles, Phenylthiohydantoin, Radioisotopes, Prostate-Specific Antigen, Taxoids, Androgen Receptor Antagonists, Prostatic Neoplasms, Castration-Resistant

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks